Ovid Therapeutics (OVID) KCC2 Download Day 2024 summary

Strategic vision and future plans

• Advancing a differentiated pipeline of over 100 KCC2 direct activators, with multiple formulations (IV, oral, intramuscular) to address acute, subacute, and chronic CNS care needs.

• OV350, the first direct KCC2 activator, is expected to enter Phase 1 human studies in Q1 2025, with readout in H1 2026, followed by additional candidates from the 4000 and 5000 series.

• Multiple compounds (OV350, OV4000, OV4071, OV5000 series) are in development for neuropsychiatric, neurodevelopmental, neurodegenerative, seizure, and pain indications.

• Indication prioritization is guided by clinical need, compound properties, and care continuum, starting with psychosis in neurodegenerative diseases.

• Strategic optionality to retain, partner, or out-license compounds based on internal expertise and indication fit, with ongoing business development and potential collaborations.

Financial guidance and resource allocation

• Cash balance of $62.7 million as of September 30, 2024, expected to fund the pipeline through H2 2026.

• Emphasis on disciplined resource use to achieve therapeutic proof of concept and maximize value for patients and shareholders.

• Multiple annual regulatory submissions planned from the KCC2 portfolio, supporting a prolific and sustainable pipeline.

• Commercial opportunity seen as significant, especially in neuropsychiatric and neurodegenerative markets with high unmet need.

• Optionality to partner or out-license compounds to accelerate development in indications outside core expertise.

Scientific and clinical highlights

• KCC2 identified as a fundamental CNS target, uniquely expressed in neurons and central to restoring inhibitory/excitatory balance.

• Direct KCC2 activation shown to restore neuronal inhibition, reduce hyper-excitability, avoid sedation, and minimize off-target effects.

• OV350 and next-generation compounds demonstrate rapid brain penetration, antipsychotic and anticonvulsant activity, efficacy in animal models, and favorable safety profiles.

• SmartCube AI-powered phenotypic screening used to map compound activity and guide indication selection.

• KCC2 activation may also reduce neuroinflammation and slow neurodegeneration, broadening therapeutic impact.